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Background: Hepatocellular carcinoma (HCC) is a common liver malignancy in Nigeria. Hepatitis B and C viruses,
alcohol and Aflatoxin B are among the various aetiologies. More work needs to be done in the search for markers
that will aid early detection of this condition as it is uniformly fatal once advanced. Alphafetoprotein (AFP) remains
the most widely used tumour marker of HCC detection in spite of its known shortcomings. The objective of this
study was to determine the efficacy of serum squamous cell carcinoma antigen (SCCA) , in comparison to
alphafetoprotein in the detection of HCC.
Method: Sixty patients with HCC and thirty apparently healthy controls attending the Medical Outpatient
Department(MOPD) of the University College Hospital Ibadan(UCH) Nigeria were selected for the study.
Questionnaire was used to collect clinical data while AFP, SCCA levels, serum HBsAg and anti-HCV were determined
using ELISA method- (Diagnostic Automation Inc. Canada). Abdominal ultrasound scan was also done.
Result: Thirty one (51.7%) out of 60 selected cases were positive for HBsAg while six (20%) out of 30 controls were
positive for HBsAg(p = 0.004). Out of the 60 cases selected for this study, only 2 (3.3.%) cases were positive for
hepatitis C virus, while only 1(3.3%) out of 30 control was positive for hepatitis C virus(p = 0.74).
The mean AFP value for cases with HCC was 393.21 ng/ml ±386.97 compared to the control group which was
5.60 ± 13.03 ng/ml (p value 0.001). The mean SCCA level was 0.64 ± 0.56 ng/ml and 0.71 ± 0.65 ng/ml for cases and
controls respectively (p = 0.631).
Conclusion: Alphafetoprotein remains a good tumour marker for the diagnosis of HCC. Serum squamous cell
carcinoma antigen(SCCA) has no discriminatory power and may not be useful as a tumour marker for Nigerians
with hepatocellular carcinoma.Background
In most parts of the world, hepatic metastases are more
common than primary malignant tumours of the liver
although the reverse is true in sub-Sahara Africa and
parts of the far East where hepatocellular carcinoma
(HCC) is the most common malignant tumour of the
liver [1]. Hepatocellular carcinoma is the sixth most
common cancer in men and women combined with
respect to the incidence rate [2]. Of the 12.7 million new
cases of cancer diagnosed worldwide in 2008,* Correspondence: soyems2002@yahoo.com
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reproduction in any medium, provided the orhepatocellular carcinoma accounted for 5.9% (748,000)
while of the 7.6 million cancer deaths worldwide in
2008, it accounted for 9.7% (1,234,000) [2].
Prevalence rate of HCC varies in different countries
within Africa and it accounts for 12% of all malignan-
cies in Nigeria [3]. The prognosis is poor due to late
presentation with advanced disease. Early detection is
still difficult due to lack of symptoms at the early stage
and biomarkers that show high sensitivity and specificity.
Alphafetoprotein (AFP), is still the only serological
marker presently available for routine screening in
Nigeria and most parts of the world. Alphafetoprotein,
discovered by Abelev in 1968 [4], is a foetal specific
glycoprotein produced primarily by foetal liver, yolkLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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falls rapidly after birth in normal conditions.
Pathological elevation of AFP is seen in hepatocyte
regeneration, hepatocarcinogenesis and embryonal car-
cinoma. Its limited utility in differentiating HCC from
benign hepatic lesions and disorders such as acute
exarcerbation of viral hepatitis has been a major draw-
back [5]. Novel tumour markers have been proposed
for the screening of hepatocellular carcinoma. These
include des-gamma carboxy prothrombin [5], Glypican
3, carbohydrate deficient transferin, Hepatitis B virus
encoded x-antigen, α – L-fucosidase and recently can-
cer testis antigen [6]. These biomarkers except DCP,
however lack adequate specificity to support a diagnos-
tic value [5,7]. On the contrary, p53 antibody as a
tumour marker is useful in predicting the grade and
stage of HCC with respect to differentiation, proliferating
activity and tumour progression [8].
Squamous cell carcinoma antigen (SCCA) is a new
tumour marker recently discovered to be of diagnostic
value in patients with hepatocellular carcinoma [9,10]. It
is a serine protease inhibitor found physiologically in the
spinous and granular layer of normal squamous epithe-
lium of the skin. Increased levels have been found in
epithelial cancers of the neck, cervix and lungs [9]. It is
reported to be highly sensitive (84.2%) compared to 60%
for AFP but has a low specificity (48.9%) for hepatocellular
carcinoma [9].
However, Gianelli and coworkers at the University of
Bari, Italy showed that a combination of AFP and SCCA
yielded a correct diagnosis in 90.8% of patients with
HCC [9]. In view of the high prevalence of HCC, the
hopeless late presentation in our population, and the
need to increase the diagnostic yield for HCC in Nigeria,
a study assessing the importance of this serological mar-
ker in comparison to AFP for detection of HCC is
desirable.
Methods
Ethical approval for this cross sectional case- control
study was obtained from the joint University College
Hospital/University of Ibadan Ethical Review Committee.
Patients with clinical, sonographical and or histopatholo-
gical confirmation of hepatocellular cancer admitted to
gastroenterology and liver units of the University College
Hospital, Ibadan were recruited for the study between
October 2009 and October 2010 after informed consents
were obtained. Patients with cancers other than primary
liver cell cancer were excluded. Controls were sex
matched apparently healthy relatives of patients with
HCC. The ultrasound features were consistent with multi-
ple intrahepatic tumours greater than 5 cm in 16 cases
with no evidence of regional lymph node metastasis (T3a,
N0,M0). Twenty- four cases were noted to involvemultiple tumours with infiltration of the branches of the
portal vein and regional lymph node metastasis (T3b,N1,
M0) while intrahepatic masses with evidence of regional
lymph nodes and distant metastasis were noted in 20 cases
(T4,NI,M1) according to the AJCC TNM classification.
A total of 60 patients with hepatocellular carcinoma
and 30 apparently healthy controls were recruited. Five
milliliters of serum sample was taken from each patient
and controls using aseptic technique and observing uni-
versal precautions. Blood samples were assayed for
serum AFP, SCCA, HBsAg and Anti-HCV antibodies.
Cut- off absorbance values were calculated according to
manufacturer’s instructions and all the cases and con-
trols with values greater than the cut- off were regarded
as positive while those equal to or less than the cut- off
were regarded as negative. Results were analyzed using
the appropriate test for continuous variables and chi
square test for analysis of quantitative variables.
Frequency tables, means, standard deviations, graphs
and diagrams were used. Significant p value was taken to
be less than 0.05. Sensitivity, specificity, positive and
negative predictive values for each individual test were
calculated while an ROC curve was used to compare the
diagnostic accuracy of one tumour marker in relation to
the other. AFP levels >200 mg/dl and SCCA levels
>0.368 ng/ml were considered positive for HCC respec-
tively in this study [9].
Enzyme immunoassay for the quantitative determination
of Afp and scca in human serum using scca and Afp Elisa
Kit (diagnostic automation Inc, Canada)
The AFP Quantitative test kit is based on a solid phase
ELISA. It utilizes one anti-AFP antibody for solid phase
(microtitre wells) immobilization and another mouse
monoclonal anti-AFP antibody in the antibody –enzyme
(horseradish peroxidase) conjugate solution. Serum was
added to the AFP antibody coated microtitre wells and
incubated with the Zero Buffer. Human AFP if present
in the serum combines with antibody on the well. The
well was then washed to remove any residual test spe-
cimen. AFP antibody labeled with horseradish peroxidase
(Conjugate) was added.
The conjugate bound immunologically to the AFP on
the well resulting in the AFP molecules being sandwiched
between the solid phase and enzyme linked antibodies.
After incubation at room temperature, the wells were
washed with water to remove unbound labeled antibodies.
A solution of TMB was added and incubated for 20 min-
utes, resulting in the development of a blue colour.
The colour development was stopped with the addi-
tion of 2 N HCL and the colour changed to yellow. This
was measured spectrophotometrically at 450 nm. The
concentration of AFP is directly proportional to the col-
our intensity of the test sample.
Table 1 Age and sex distribution
Characteristics Cases (n = 60) Control (n = 30) Total (n = 90 X2 – value P- value
1. Age group (years)
<30 10 (16.7) 14 (46.7) 24 (26.7)
30-39 16 (26.7) 5 (16.7) 21 (23.3)
40-49 9 (15.0) 2 (6.7) 11 (12.2) 10.275 0.036
50-59 13 (21.7) 3 (10.0) 16 (17.8)
60+ 12 (20.0) 6 (20.0) 18 (20.0)
2. Sex
Male 40 (66.7) 20 (66.7) 60 (66.7) 0.000 1.000
Female 20 (33.3) 10 (33.3) 30 (33.3)
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was transferred to a strip frame and washed with the
Wash solution. 25 μl of SCC Calibrators and serum sam-
ple was put into the strip well and 100 μl of antibody
solution was added. After incubation at room tempera-
ture, each strip was washed six times before addition of
TMB HRP – substrate to each well. This was incubated
again for 30 minutes. The absorbance was measured
spectrophotometrically at 620 nm.Results
There was male predominance among the patients, 40
being males (66.7%) compared to 20 (33.3%) females with
a male to female ratio of 2:1. Similar values were obtained
among controls. Ten (16.7%) of the cases were below the
age of 30. Sixteen (26.7%) were between the ages of 30
and 39 years. Nine (5%) were within the 40–49 years age
range. Thirteen (21.7%) were between 50–59 year age
range while twelve (20%) were >60 yrs of age. The modal
age range was between 30–39 years. There was no signifi-
cant difference in the sex ratio of cases and control
(p = 1.00) (Table 1).
Of the 60 cases of HCC, 31 (51.7%) were positive
for HBsAg as compared to six (20%) of the control
group (p 0.004). Similarly anti HCV were present in 2
cases (3.3%) compared to 1 patient (3.3%) in the control
group (Table 2).Table 2 Prevalence of HBsAg & HCV among patients with HC
Characteristics Cases (n = 60) Control (n = 30)
HBsAg
Yes 31 (51.7) 6 (20.0)
No 29 (48.3) 24 (80.0)
HCV
Yes 2 (3.3) 1 (3.3)
No 58 (96.7) 29 (96.7)The mean AFP value for cases with HCC was
393.21 ± 386.97. This was considerably higher than the
mean AFP level for the control group which was
5.60 ± 13.03 ng/ml (p value = 0.001). The range values for
AFP in cases with HCC were between 1.68 ng/ml to
>812.45 ng/ml which was the upper limit for concentra-
tion measurable by the kit used while the AFP range for
control was between 0.43 – 72.95 ng/ml (Table 3).
Thirty one of the cases (51.7%) had AFP values above
200 ng/ml. None of the controls had significantly ele-
vated AFP levels. The sensitivity of the test was noted to
be 51.7% while the specificity was 100%. The positive
predictive value was equal to 100% and the negative pre-
dictive value was 49.2% (Table 4).
SCCA sensitivity was noted to be 75% while the speci-
ficity was 26.7%. The positive predictive value was 67.2%
and the negative predictive value was 65.2% (Table 4).
Only 26 patients with hepatocellular carcinoma had
both positive AFP > 200 ng/ml and SCCA> 0.368 ng/ml.
None of the controls had a combined AFP and SCCA
value greater 200 ng/ml and 0.368 ng/ml respectively. A
combination of positive AFP (>200 ng/ml) and positive
SCCA (>0.368 ng/ml) increased the specificity to 100%
(Table 4).
The AUC quantifies the overall ability of the test to
discriminate between those individuals with the disease
and those without. A perfect test with zero false posi-
tives and zero false negatives has an area of 1.00. TheC and control
Total (n = 90) X2 -value P-value
37 (41.1) 8.284 0.004
53 (58.9)
3 (3.3) 0.000 0.743
87 (97.7)
Table 3 Comparison of AFP & SCCA cases and control
AFP Cases Control T-Value P-Value
Mean± SD 393.21 ± 386.97 5.60 ± 13.03 5.455 0.001
Range 1.68-812.45 0.43-72.95
SCCA
Mean± SD 0.64 ± 0.56 0.71 ± 0.65 −0.482 0.631
Range 0.15 – 3.56 0.02 – 2.65
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compared to SCCA with an area of 0.525 (Table 5).
The receiver operating characteristic curve (ROC) for
alphafetoprotein is closer to the left hand border and the
top upper left corner. This reflects its accuracy as a good
screening test for hepatocellular carcinoma compared to
squamous cell carcinoma antigen which is closer to the
diagonal.
Discussion
Alphafetoprotein values were frequently elevated in
patients with HCC. AFP values >200 ng/ml was seen in
51.7% (31 cases) compared to controls. This is signifi-
cantly lower than the 75% and 85% obtained by Alpert
[11] and Fakunle [12]. It validates previous studies that
have found that not all patients with hepatocellular car-
cinoma elaborate this tumour marker [5,7]. Values for
SCCA were similar in both cases and control with no
significant statistical difference (p = 0.631).
In this study AFP had an AUC of 0.916 which makes
it a good screening test for the diagnosis of hepatocellu-
lar carcinoma. This was quite higher than the 0.717
found by Gianelli [9] in his own study which looked at
the immunohistochemistry of liver tissues with hepato-
cellular carcinoma.
AUC for SCCA was noted to be 0.525 with a 95% con-
fidence interval of 0.389-0.661. This study did not find a
significant level of discriminatory power of SCCA
between HCC patients and healthy control groups unlike
previous studies [9,10]. This may be explained by the
fact that previous studies involved tissue specimens ofTable 4 Serum AFP in patients with HCC and controls (Levels
Serum AFP




Positive 31 0 45
Negative 29 30 15
Sensitivity 51.7% 75%
Specificity 100% 26.7%
Positive predictive value 100% 67.2%
Negative predictive value 49.2% 65.2%
Accuracy 67.7% 58.8%both primary nodules of HCC and peritumoural areas.
They performed Immunohistochemistry quantification
on tissue specimens. SCCA antigen appeared strongly
stained in tumoral tissues [9,10]. However, no correla-
tion was observed between serum and tissue levels of
SCCA antigen (r =−0.094, p > 0.1) [9,10]. SCCA is
mainly expressed in cytosol and is not associated with
membrane bound organelles, therefore circulating serum
levels are likely due to cell lysis rather than a secretory
process. This may account for why serum SCCA may
not be ideal discriminatory marker for HCC diagnosis.
SCCA sensitivity was 75%, compared to AFP sensitiv-
ity of 51.7%. It compares favorably with work done by
Gianlugi Giannelli et al [9] where SCCA sensitivity was
84.2%. However the specificity of SCCA in our study
was poor (26.7%), compared to AFP specificity of 100%.
The specificity was also poor in the study by Gianluigi
Gianneli (48.9%). This antigen is noted to be common in
the skin, saliva and sweat of apparently normal people
and this may account for the values that were found in
the controls.
There are therapeutic techniques for the treatment of
hepatocellular carcinoma in the early stage; hence, empha-
sis is now being placed on early detection in patients at risk
who are presently asymptomatic. Detection of HCC at an
early stage may reduce mortality significantly. Mass screen-
ing may be justified as the population at-risk can be identi-
fied easily and tumour ablation or resection at an early
stage can increase survival. However, massive screening
should be justified only when sensitive and specific diagnos-
tic procedures are available.
Des- gamma- carboxy- prothrombin (DCP) is another
promising tool with limited expense and wide accessibility.
A bivariate meta- analysis of the diagnostic performance of
DCP by Gao et al [5] found a sensitivity of 67%, specificity
of 92%, positive likelihood ratio of 92% and an AUC of
0.89. They however noted significant heterogeneity and
recommended more prospective studies. DCP assay was
not one of the objectives in this present study, however, it is
recommended for future considerations.>200 ng/ml is considered positive)
A
68 ng/ml
Combination of serum AFP>200 ng/ml









Table 5 Area under the curve for quantifying discriminatory power of a test for those with and without HCC
Test variables Area Std. error P-value 95% confidence interval
Alpha-fetoprotein 0.916 0.029 0.001 0.860-0.973
Squamous cell carcinoma antigen 0.525 0.069 0.700 0.389 – 0.661
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been approved for widespread clinical use in the screen-
ing of patients with hepatocellular carcinoma. It is also
very expensive. Unfortunately as shown in this study, it
also lacks good discriminatory power between with HCC
and apparently healthy controls and may not be useful in
this subset of patients. We noted that all the cases
recruited into this study presented with advanced hepa-
tocellular carcinoma and died within 3 months of presen-
tation, reflecting the poor prognosis at this stage. Present
recommendation focuses on 6 monthly ultrasound sur-
veillance and measurement of serum Alphafetoprotein in
patients with chronic hepatitis and or cirrhosis.
Thirty one cases (51.7%) were found to be HBsAg
positive in this study. This represents a significant asso-
ciation between HCC and HBV as an aetiological agent
in this study.
Previous study by Ndububa [13] noted a prevalence of
61% of HBsAg in HCC. Our study did not find a signifi-
cant difference between HCV infection in cases and con-
trol. Only 2 cases and 1 apparently healthy control were
positive for HCV. While the risk was not significant in
this study, it has however been well proven that HCV is
an important aetiological risk factor for the development
of hepatocellular carcinoma. This is especially true in
Western Europe and Asia [14-16].
Van Roey [16] found that 55% of HBsAg negative cir-
rhotic patients with HCC were anti-HCV positive. The
reduced prevalence found in our study suggests that
HCV infection may not be a strong risk factor compared
to hepatitis B in our patients.
More work need to be done in search of appropriate
tumour markers for early detection of hepatocellular
carcinoma among Nigerians.
The scope of this study was limited majorly by funds.
However, future studies will consider inclusion of con-
trols with cirrhosis and metastatic liver disease. Another
major limitation was the inability to study the efficacy of
SCCA in patients with early HCC due to late presenta-
tion in our environment. This is reflected in our study
where all the patients presented with advanced HCC.Conclusions
We conclude that AFP remains a relatively good screen-
ing marker for HCC in Nigerians and SCCA lacks accu-
racy as a screening test for its diagnosis in Nigerians.
Hepatitis B remains a strong aetiological agent of livercancer in Nigeria and efforts at childhood immunization
will help in reducing the disease burden.
Competing interests
The authors of this article hereby declare that they have no competing
interests.
Authors’ contributions
Dr Soyemi Olufemi: Conceptualization and design of study, Drafting of
Article. Dr Otegbayo Jesse Abiodun: Critical Review of Article for intellectual
content. Dr Ola Samuel Olawale: Manuscript Review. Dr Akere Adegboyega:
Literature Search. Dr Soyemi Temitope: Manuscript preparation, acquisition of
Data. All authors read and approved the final manuscript.
Acknowledgement
We would like to appreciate the contributions of staff of the Department of
Virology, University College Hospital Ibadan, especially Professor D.O Olaleye
and Dr.G.N.Odaibo for the storage and subsequent processing and analysis
of the serum samples of the selected patients and controls used for this
study.
We also acknowledge Dr Adedokun of the faculty of preventive medicine for
his contribution to the study design and the statistical interpretation of the
results of this study.
The research was solely funded by the principal investigator (Dr Soyemi
Olufemi Michael) for academic purposes and the furthering of knowledge.
Author details
1Gastroenterology, Department of Medicine, University College Hospital,
Ibadan, Oyo State, Nigeria. 2Liver and Gastrointestinal unit, Department of
Medicine, University College Hospital, Ibadan, Nigeria. 3Liver and
Gastrointestinal Unit, Department of Medicine, University College Hospital,
Ibadan, Nigeria. 4Liver and Gastrointestinal Unit, Department of Medicine,
University College Hospital, Ibadan, Nigeria. 5Department of Radiology,
University College Hospital, Ibadan, Nigeria.
Received: 12 March 2012 Accepted: 26 July 2012
Published: 3 August 2012
References
1. Feldman M, Friedman LS, Sleisenger MH, Scharschmidt BF: Sleisenger and
Fordtran’s Gastrointestinal and liver disease. Pathophysiology / Diagnosis /
Management. Seventhth edition. Philadelphia: Saunders; 2002:15 79–582.
1589–1590. ISBN Volume II.
2. International agency for research on cancer (IARC): GLOBOCAN Report World
Health Organisation(WHO); 2008.
3. Kew MC: Epidemiology of Chronic hepatitis B virus Infection.
Hepatocellular carcinoma and Hepatitis B virus induced hepatocellular
carcinoma. Pathol Biol 2010, 58:273–277.
4. Abelev GI: Production of embryonal serum alpha- globulin by
hepatomas: Review of experimental and clinical data. Canc Res 1968,
28:1344–1350.
5. Gao P, Li M, Tian QB, Liu DW: Diagnostic performance of Des-gamma-
carboxy- prothrombin (DCP) for hepatocellular carcinoma: A bivariate
Meta-analysis. Neoplasma 2012, 59(2):150–159.
6. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M,
et al: Usefulness of cancer- testis antigens as biomarkers for the
diagnosis and treatment of hepatocellular carcinoma. J Transl Med
2007, 5:3.
7. Trojan J, Raedle J, Zeuzem S: Serum tests for diagnosis and follow up of
hepatocellular carcinoma after treatment. Digestion 1998,
59(Suppl 2):72–74.
Soyemi et al. BMC Research Notes 2012, 5:403 Page 6 of 6
http://www.biomedcentral.com/1756-0500/5/4038. Akere AO, Otegbayo JA: Evaluation of the pattern and prognostic
implications of anti P53 antibody in hepatocellular carcinoma. Singapore
Med J 2007, 48:41–44.
9. Giannelli G, Marinosci F, Trerotoli P, Volpe A, Quaranta M, Dentico P: SCCA
combined with alphafetoprotein as serological markers of hepatocellular
carcinoma. Int J Cancer 2005, 117:506–509.
10. Pontisso P, Calabrese F, Benvegnu L, Lise M, Belluco C, Ruvoletto MG, et al:
Overexpression of squamous cell carcinoma antigen variants in
hepatocellular carcinoma. Br J Cancer 2004, 90:833–837.
11. Alpert E, Feller ER: Alpha- fetoprotein (AFP) in benign liver disease:
Evidence that normal liver regeneration does not induce AFP synthesis.
Gastroenterology 1978, 74:856–858.
12. Fakunle YM, Ajdukiewicz AB, Greenwood BM, Edington GM: Trans R Soc Trop
Med Hyg 1977, 71:335–337.
13. Ndububa DA, Ojo OS, Adeodu OO, Adetiloye VA, Olasode BJ, Famurewa OC,
et al: Primary hepatocellular carcinoma in Ile Ife, Nigeria: a prospective
study of 154 cases. Niger J Med 2001, 10:59–63.
14. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors and
screening. Semin Liver Dis 2005, 25(2):143–154.
15. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al:
Hepatitis C-related hepatocellular carcinoma in the United States:
influence of ethnic status. Am J Gastroenterol 2003, 98(9):2060–2063.
16. Van Roey G, Fevery J, Van Steenbergen W: Hepatocellular carcinoma in
Belgium: clinical and virological characteristics of 154 consecutive
cirrhotic and non- cirrhotic patients. Eur J Gastroenterol Hepatol 2000,
12(1):61–66.
doi:10.1186/1756-0500-5-403
Cite this article as: Soyemi et al.: Comparative diagnostic efficacy of
serum squamous cell carcinoma antigen in hepatocellular carcinoma.
BMC Research Notes 2012 5:403.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
